Lifespan of mice and primates correlates with immunoproteasome expression

Andrew M. Pickering, Marcus Lehr, and Richard A. Miller

Department of Pathology and Geriatrics Center, University of Michigan, Ann Arbor, Michigan, USA.

Introduction

Within the animal kingdom there is extraordinary variation in lifespan. Members of some species only live a few days or weeks, while others live tens, if not hundreds, of years. This large variation in species lifespan found in nature provides a powerful tool for the identification of factors that regulate the rate of aging.

There is now a body of evidence to suggest that primary skin-derived fibroblasts can be used to evaluate aspects of cell biology that may differ between long-lived and short-lived species. This approach is not based on any assumption that changes in fibroblast properties would significantly affect organismal lifespan, but rather on the notion that evolutionary changes that produce slow aging might affect multiple cell types, including some that contribute to long-lasting resistance to disease and disability, as well as others, like fibroblasts, that are easy to cultivate and expand under standardized conditions for scores of species in parallel.

We have previously reported, using large-scale, cross-species comparisons, that fibroblasts from long-lived primates, rodents, laurasiatheria, and bird species are less susceptible to protein damage following oxidative stress than primary cells from shorter-lived species from these respective, independent clades (1). In addition, fibroblasts from long-lived rodent and bird species require higher doses of a range of oxidants to cause lethality than do fibroblasts from shorter-lived species (2, 3). Similar findings have been made by other studies using smaller sets of animals (4–6). It has also been shown that telomerase activity is higher in larger longer-lived species from these respective, independent clades (1). In addition, fibroblasts from long-lived primates and rodents have elevated levels of proteasomal activity compared with laboratory mice, as well as increased expression of a variant of the proteasome known as the immunoproteasome (24). Fibroblasts from healthy centenarians have been reported to exhibit higher proteasomal activity than fibroblasts taken from typical healthy young or elderly donors (25). Each of these lines of evidence provides support for the idea that proteasomal function may help regulate the rate of aging and lifespan.

Many of the mutations, diets, and drugs that can extend lifespan in mice, flies, and worms increase resistance to oxidative stress (6, 8–12), supporting the idea that cellular resistance to oxidative stress may help to regulate aging rate and lifespan. In contrast, many experiments in which specific agents involved in oxidant defenses have been modulated in mice and other animals have shown little or no effect on lifespan, as reviewed in refs. 13 and 14. These findings have led to a more nuanced view that while oxidative stress resistance itself may not regulate lifespan, increased resistance of cells to oxidative injury and protein damage may be a consequence of underlying changes in factors that do regulate lifespan. It remains to be determined whether the increase in oxidative stress resistance brought about by these factors is directly linked to increased lifespan or is merely a side effect of these cellular changes.

There is some evidence that modulation of proteasome function may play an important role in the pace of aging and control of lifespan across species. Various forms of proteasomes have been reported as important in protein turnover and the removal of oxidized proteins (15, 16). Boosted expression of proteasome subunits has been shown to increase lifespan in worms and yeast (17, 18). Proteasome levels and activity have been reported to decline with aging in a wide range of tissues in humans and other mammals (19, 20). Age-related declines in proteasome function have been shown to contribute to a wide range of age-related diseases (21–23). Similarly, liver samples from the long-lived naked mole rat have elevated levels of proteasomal activity compared with laboratory mice, as well as increased expression of a variant of the proteasome known as the immunoproteasome (24). Fibroblasts from healthy centenarians have been reported to exhibit higher proteasomal activity than fibroblasts taken from typical healthy young or elderly donors (25). Each of these lines of evidence provides support for the idea that proteasomal function may help regulate the rate of aging and lifespan.
We previously reported that fibroblasts from longer-lived non-human primate species have greater proteolytic activity than cells from shorter-lived species, but there is no significant lifespan association with 20S proteasome activity (Figure 1A). We found that 20S proteasome activity was significantly higher in fibroblasts from longer-lived primates compared with shorter-lived primates (Figure 1B; $R^2 = 0.21$, $P = 0.03$ and Supplemental Figure 2). We observed a similar trend for ATP-stimulated proteasome activity, but this did not reach statistical significance (Supplemental Figure 1B; $R^2 = 0.18$, $P = 0.09$). In this experiment and in all other experiments reported herein, humans represent a clear outlier; for this reason, the responses of human cells are indicated with an “H” in each figure, but the data from humans are not used in the statistical analyses. Our conclusions thus pertain strictly to non-human primate species.

As an independent and more specific measure of proteasome activity, we performed an in-gel overlay assay. In this assay, cell lysate was run on a native polyacrylamide gel and then incubated with the chymotrypsin-like substrate Suc-LLVY-AMC. One μg of purified human 20S and 0.1 μg of purified 26S proteasome samples were run alongside cell lysates as a loading control and to confirm band identity (Figure 1A). We found that 20S proteasome activity was significantly higher in longer-lived primates compared with shorter-lived primates (Figure 1B; $R^2 = 0.21$, $P = 0.03$ and Supplemental Figure 2). In contrast, we saw no significant association of species MLS with 26S proteasome activity (Figure 1C; $R^2 = 0.03$, $P = 0.47$).

To investigate the basis for the increase in proteasome activity at the 20S band in cells from longer-lived primates, we prepared immunoblots of native polyacrylamide gels similar to those used for the activity assays and measured proteasome levels using an antibody against the proteasome subunit PSMB5 (also known as β5). PSMB5 is a proteolytically active subunit that is critical to the assembly and function of the proteasome. In addition, the synthesis of PSMB5 has been reported as rate limiting to proteasome assembly, making it a good surrogate for measuring proteasome levels (26). We found no significant correlation between PSMB5 levels and species MLS (Figure 2, A and B; $R^2 = 0.08$, $P = 0.31$).

We went on to look at an alternative form of the 20S proteasome known as the immunoproteasome. The 20S immunoproteasome is nearly identical in size to the 20S proteasome and differs only by 3 alternate subunits, PSMB8 (also called LMP7 or β5i), PSMB9 (also called LMP2 or βi), and PSMB10 (also called MECL1 or β2i), which replace PSMB5, PSMB1, and PSMB2, of proteasome activity, we measured the capacity of cell lysate derived from long- and short-lived primate species to degrade the chymotrypsin-like substrate Suc-LLVY-AMC. Activity was measured in the absence and presence of ATP to distinguish the activity of the ATP-independent 20S proteasome and the ATP-dependent 26S proteasome (15, 16). We observed a significant association between ATP-independent proteolytic activity and species maximum lifespan (MLS) ($R^2 = 0.36$, $P = 0.01$, Supplemental Figure 1A; supplemental material available online with this article; doi:10.1172/JCI80514DS1). We observed a similar trend for ATP-stimulated proteolytic activity, but this did not reach statistical significance (Supplemental Figure 1B; $R^2 = 0.18$, $P = 0.09$). In this experiment and in all other experiments reported herein, humans represent a clear outlier; for this reason, the responses of human cells are indicated with an “H” in each figure, but the data from humans are not used in the statistical analyses. Our conclusions thus pertain strictly to non-human primate species.

In this report we show that fibroblasts from longer-lived species of primates have greater proteolytic activity than cells from shorter-lived primates. Cells from the longer-lived species do not have an increase in standard proteasome levels. Instead, the elevation of proteolytic activity is produced by increases in an alternative form of proteasome known as the immunoproteasome. Increases in expression are also observed in other aspects of the MHC antigen presentation pathway, including expression of IFN-γ receptor protein 2 (IFNGR2), β-2 microglobulin, transporter associated with antigen processing 1 (TAP1), and TAP2, as well as sensitivity to IFN-γ. Immunoproteasome and proteasomal activity was also found to be elevated in liver tissue from mice in which longevity was increased either through a single gene mutation or following exposure to drugs that extend lifespan, some of them with parallel, sex-specific effects.

Results

We previously reported that fibroblasts from longer-lived non-human primate species incur less protein damage following oxidative stress than fibroblasts derived from shorter-lived primate species (1). Such differences in stress resistance could occur through differences in cellular capacity to remove oxidants or in capacity to remove oxidant-damaged proteins. We hypothesized that if cells from longer-lived primates have increases in protein turnover, this might reflect increased proteasome activity. As an initial index of proteasome activity, we measured the capacity of cell lysate derived from long- and short-lived primate species to degrade the chymotrypsin-like substrate Suc-LLVY-AMC. Activity was measured in the absence and presence of ATP to distinguish the activity of the ATP-independent 20S proteasome and the ATP-dependent 26S proteasome (15, 16). We observed a significant association between ATP-independent proteolytic activity and species maximum lifespan (MLS) ($R^2 = 0.36$, $P = 0.01$, Supplemental Figure 1A; supplemental material available online with this article; doi:10.1172/JCI80514DS1). We observed a similar trend for ATP-stimulated proteolytic activity, but this did not reach statistical significance (Supplemental Figure 1B; $R^2 = 0.18$, $P = 0.09$). In this experiment and in all other experiments reported herein, humans represent a clear outlier; for this reason, the responses of human cells are indicated with an “H” in each figure, but the data from humans are not used in the statistical analyses. Our conclusions thus pertain strictly to non-human primate species.

As an independent and more specific measure of proteasome activity, we performed an in-gel overlay assay. In this assay, cell lysate was run on a native polyacrylamide gel and then incubated with the chymotrypsin-like substrate Suc-LLVY-AMC. One μg of purified human 20S and 0.1 μg of purified 26S proteasome samples were run alongside cell lysates as a loading control and to confirm band identity (Figure 1A). We found that 20S proteasome activity was significantly higher in longer-lived primates compared with shorter-lived primates (Figure 1B; $R^2 = 0.21$, $P = 0.03$ and Supplemental Figure 2). In contrast, we saw no significant association of species MLS with 26S proteasome activity (Figure 1C; $R^2 = 0.03$, $P = 0.47$).

To investigate the basis for the increase in proteasome activity at the 20S band in cells from longer-lived primates, we prepared immunoblots of native polyacrylamide gels similar to those used for the activity assays and measured proteasome levels using an antibody against the proteasome subunit PSMB5 (also known as β5). PSMB5 is a proteolytically active subunit that is critical to the assembly and function of the proteasome. In addition, the synthesis of PSMB5 has been reported as rate limiting to proteasome assembly, making it a good surrogate for measuring proteasome levels (26). We found no significant correlation between PSMB5 levels and species MLS (Figure 2, A and B; $R^2 = 0.08$, $P = 0.31$).

We went on to look at an alternative form of the 20S proteasome known as the immunoproteasome. The 20S immunoproteasome is nearly identical in size to the 20S proteasome and differs only by 3 alternate subunits, PSMB8 (also called LMP7 or β5i), PSMB9 (also called LMP2 or βi), and PSMB10 (also called MECL1 or β2i), which replace PSMB5, PSMB1, and PSMB2,
respectively. To measure immunoproteasome levels, we used an antibody against PSMB8. PSMB8 was chosen as it is reported to be rate limiting for immunoproteasome assembly and controls synthesis of the other two immunoproteasome-specific subunits (27). In addition, because PSMB8 replaces PSMB5, this approach avoids potential complications from cross-reactivity between proteasome forms in the 2 immunoblots. We observed a significant correlation of PSMB8 levels with species MLS (Figure 2C; \( R^2 = 0.29, P = 0.04 \)). This suggests that the increase in proteolytic activity seen with species lifespan in primates is not caused by an increase in standard proteasome, but instead by differences in immunoproteasome synthesis. In a separate experiment, 4 human cell lines were contrasted with cell lines derived from a range of great ape species. In this comparison humans were found to have similar levels of PSMB8 to other members of the great apes radiation. To confirm our findings, we prepared a second, independent set of cell lysates for 19 primate species. In these new samples, we again found a significant association between MLS and PSMB8 expression, but no significant association for PSMB5. In these confirmatory experiments we also measured PSMB4, which is present in both forms of proteasome. When levels of PSMB5 or PSMB8 were normalized with respect to PSMB4 (instead of to total protein content of the lysate), we continued to see a significant association between PSMB8 expression and lifespan but no significant association for PSMB5 (Supplemental Figure 3).

We considered the possibility that differences among species in PSMB8 band intensity in the immunoblots might be due not to differences in protein levels but instead to differences in the protein-binding affinity of antibodies across species. To minimize this possibility, we chose antibodies for which the sequence of the epitope could be compared to the sequences of the 12 primate species for which sequence data have been made available by the National Center for Biotechnology Information (NCBI). The antibodies used for PSMB5 and PSMB4 (ab3330 and ab166792, respectively; each purchased from Abcam) target epitopes that are 100% conserved in all 12 species. The antibody chosen for PSMB8 (ab3329; purchased from Abcam) binds to a sequence that is 100% conserved in 9 of the 12 species and contains small sequence variations in the other 3 species (Supplemental Figure 4A). To test whether these sequence variations would cause differences in antibody binding affinity, we performed an ELISA assay against a range of concentrations of synthetic peptides of these epitopes. When this was performed only one peptide, corresponding to the orangutan epitope, was found to have significantly lower binding affinity to the PSMB8 antibody (Supplemental Figure 4B). The orangutan is a long-lived primate (MLS 59 yr), and orangutan cells were found to have high expression levels of PSMB8 (Figure 2A). As a result, even if the PSMB8 antibody binding efficiency is lower for this species than it is for other species, adjustment for such an effect would only strengthen the lifespan-dependent trend for PSMB8.

As a further check on this observation, we measured *PSMB8* mRNA expression and observed a significant increase in *PSMB8* mRNA expression with species MLS (Figure 3A; \( R^2 = 0.32, P = 0.007 \)). In contrast, we observed no significant increase in the mRNA for the proteasome subunit *PSMB5* (Figure 3B; \( R^2 = 0.06, P = 0.28 \)). In these experiments we took care to design primers that would target sequences that are highly conserved among primate species (Supplemental Figure 5).

We were interested to determine whether the immunoproteasome is differently regulated between long- and short-lived primate species. One of the major regulators of immunoproteasome
is IFN-γ, which acts through the JAK/STAT pathway (27). When we cultured cells with IFN-γ for 24 hours, we found an increase in PSMB8 expression in cells from longer-lived species, but saw no increase — and in some cases saw a decrease — in cells from shorter-lived species (Figure 3C; $R^2 = 0.23, P = 0.03$).

We also found that exposing cells from longer-lived primates to IFN-γ produced a small increase in resistance to peroxide-induced cell death. In contrast, no increase in peroxide resistance was observed in cells from shorter-lived primate species, and some short-lived species even showed a decline in stress resistance following IFN-γ treatment. Representative data are shown for L’Höest’s monkey cells (MLS 24.1 yr) (Figure 3D) and Gorilla cells (MLS 55.4 yr) (Figure 3E) as examples of short- and long-lived species, respectively. Figure 3F shows the regression of induced peroxide resistance against species lifespan ($R^2 = 0.38, P = 0.0006$). Low levels of IFN-γ have been reported in fetal bovine serum, in which sequence divergence, which are more dramatic when New World primates, lorises, and lemurs are considered (Supplemental Figure 7). As a second, independent measure of IFNGR2 expression, we measured IFNGR2 mRNA levels. We found much higher levels of IFNGR2 mRNA in cells from longer-lived species, with an exponential association with species lifespan (Figure 4C; $R^2 = 0.42, P = 0.001$). The association between IFNGR2 mRNA and lifespan is significant when fitted to a linear regression as well, although there is a better fit to an exponential regression. The primers used were complementary to sequences that are highly conserved among primate species (Supplemental Figure 8). We expanded our analysis to examine other members of the JAK/STAT signaling cascade and noted a significant association with lifespan in STAT1 mRNA levels and species life span, and particularly among primate species (Supplemental Figure 9).

The immunoproteasome has been reported to play an important role both in degradation of oxidized proteins (16, 29, 30) and in generation of peptides for MHC class I antigen presentation (31, 32). We wished to determine whether the increase in immunoproteasome in cells of longer-lived primate species was accompanied by an increase in other aspects of MHC class I antigen presentation. First we looked at the TAP proteins. These proteins serve to transport peptides that are generated by the immunoproteasome to the ER, where they are further processed and then presented on the cell surface membrane (33). We observed a significant association between TAP1 and TAP2 mRNA expression and species lifespan (Figure 5, A and B; TAP1: $R^2 = 0.29, P = 0.02$; TAP2: $R^2 = 0.25, P = 0.03$). In addition we saw a similar association between β-2 microglobulin mRNA expression and lifespan (Figure 4C; $R^2 = 0.25, P = 0.03$). β-2 Microglobulin is a highly conserved part of the MHC class I complex (34) and is also involved in several forms of “non-classical” MHC class I antigen presentation (35). As described above, we took care to design primers that would target sequences that are highly conserved among primate species (Supplemental Figures 10 and 11). It was not possible to quantify protein levels of these factors due to lack of availability of antibodies that target sufficiently conserved epitopes for these proteins.

Interpretation of species comparisons can be complicated by variation in phylogenetic distances among species. Closely related species would be expected to have a similar lifespan and gene
expression profile, even if there were no causal relationship. This has the potential to produce misleading conclusions. For instance, great apes typically live approximately 30 to 40 years longer than lemurs, but many differences exist between these primate groups that are unrelated to lifespan (e.g., tail length). To evaluate the issue of phylogenetic relatedness in our datasets, we conducted a standardized phylogenetic-independent contrast analysis (36). This contrast was based on the phylogeny shown in ref. 1. This contrast was performed on results for ATP-independent proteolytic activity, PSMB8 mRNA, IFNGR2 mRNA, and IFN-\(\gamma\) responsiveness. In each case the significant trends persisted even after correction for phylogenetic relatedness (\(P = 0.01\) for proteolytic activity, \(P = 0.005\) for PSMB8 expression, \(P = 0.03\) for IFNGR2 mRNA, \(P = 0.006\) for IFN-\(\gamma\) responsiveness; see Supplemental Figure 12).

A second potential complication comes from the association of lifespan and body mass across species. There is a strong correlation between species body mass and lifespan among mammalian species. This is potentially the result of relaxed predator pressure and longer post-natal development times among the larger species, which tend to occupy ecological niches that select for longer lifespan. Such an association might lead to a spurious association between longevity and cellular traits if the later are in fact linked to species differences in mass (37). On the other hand, adjustment for body mass is likely to obscure associations that do indeed reflect causal associations, because diluting statistical trends by adjustment for a common covariate (mass) will increase type II errors. The association between lifespan and ATP-independent proteolytic activity remained significant even after adjustment for body mass (\(P = 0.005\)), as did the association with response to IFN-\(\gamma\) response (\(P = 0.01\)), but as expected, adjustment for mass weakened the strength of each correlation, and after adjustment the regressions for PSMB8 (\(P = 0.28\)) and IFNGR2 (\(P = 0.08\)) were no longer statistically significant (Supplemental Figure 13).

The cell lines available to us vary somewhat in both passage number and in the age of the donor animal (summarized in Supplemental Table 1). Several groups have reported elevations of immunoproteasome with organismal aging in muscle, retina, and hippocampus tissue derived from mice and rats (29, 38–40) as well as with continued passage of primary cells in culture (41). To reduce artifacts of this kind, we used cell lines at the lowest practical passage number, with only 1 cell line used at a passage above 20. We also selected cell lines from adult donors in good health, and only 4 of the cell lines were derived from donors older than 50% of the species MLS (see Supplemental Table 1). In principle, the observed association of species MLS to PSMB8 expression might reflect confounding by donor age or passage number if either varied systematically with MLS, but the scatter plots in Supplemental Figure 14 show no significant relationship between MLS and either passage number or donor age as a fraction of MLS. As a further test of this concern, we reevaluated the relationship of key endpoints, including PSMB8 levels, 20S proteasome activity, and IFN\(\gamma\) mRNA, using data from which the 4 oldest donors (donors whose age exceeded 50% of their species MLS) were excluded. The results using this trimmed set of species, as shown in Supplemental Figure 15, did not differ substantially from those derived from the full data set. We conclude that the associations between cellular properties and species MLS noted in the main figures do not reflect artifacts of cell passage number or donor age.

The association of immunoproteasome abundance and proteolytic activity with species longevity suggested that modifications in proteasome structure or function might be seen in mice whose lifespan had been increased by drug treatment or by genetic mutation. We therefore tested mice exposed to each of 3 drugs previously shown to extend mouse lifespan: (a) the TOR inhibitor rapamycin (42), (b) the antioxidant, antiinflammatory agent nordihydroguaiaretic acid (NDGA) (43, 44), and (c) the non-feminizing...
steroid 17α-estradiol (EST) (44) in male mice only (44). In addition, we evaluated Snell dwarf mice, in which a mutation in the Pit1 gene extends lifespan, in both sexes, by disrupting pituitary production of growth hormone, thyroid-stimulating hormone, and prolactin (45, 46). Each of the 3 drugs and the mutation led to an elevation in liver PSMB8 protein levels, used as a surrogate for immunoproteasome (Figure 6). A 2-factor ANOVA was used to evaluate the effects of sex, treatment, and interaction. The main effect for treatment was significant at $P \leq 0.007$ for each comparison. PSMB8 levels in liver were also higher in females compared with males for the UM-HET3 mice used in the drug studies. In none of the 4 datasets was there a significant (treatment × sex) interaction effect, except for NDGA, in which female mice showed larger drug effects than males. Rapamycin and NDGA also led to significant increases in proteasomal activity (Figure 7), and though there were trends toward increased proteasomal function in liver of EST and Snell dwarf mice, these did not reach statistical significance, nor did we see statistically significant interaction effects in the ANOVA analysis. Supplemental Table 2 shows the detailed results of each ANOVA calculation, as well as intergroup comparisons using the least significant difference post hoc test. We evaluated both PSMB8 levels and proteasome function in liver lysates from mice treated with acarbose, an agent that increases longevity dramatically in male mice and slightly in females (44), but we saw no effect of this drug on either endpoint (data not shown).

**Discussion**

Comparison of the properties of cells from long-lived and short-lived species is proving a valuable tool to identify factors that help to regulate lifespan and aging rates among mammals. Much recent progress in biogerontology has involved studies of diets (47), drugs (44, 48), and mutations (49) that increase longevity, but none of these approaches has to date exceeded a 60% extension in lifespan. In contrast, lifespan differences between related species can be much larger. For example, the longest-lived primate species lives roughly 8-fold longer than the shortest-lived primate species (MSL 122.5 yr compared with MSL 16 yr) (50). Studies of cellular properties among species, however, can be complicated by species-specific variation in protein and gene sequences, which complicates routine deployment of standard immunoblotting and RT-PCR methods. These obstacles can be particularly troubling for species whose genome has not yet been sequenced. Nonetheless, recent advances in genetic sequencing have reduced this constraint, and there is now an increasing range of mammals for which at least partial gene, mRNA, and protein sequence data are available. Such information helps in the choice of probes and antibodies, which can be targeted at relatively conserved regions of protein and genetic sequence, particularly for clades, like the primate radiation, for which many species have already been sequenced. Data on primate aging may prove to be especially germane to questions about human health and lifespan, but there are serious practical and ethical barriers to studies of live primates. One goal of our strategy is to understand to what extent differences among primates of varying longevity modulate the properties of their corresponding skin-derived fibroblast cell lines.

The immunoproteasome is an alternative form of the standard 20S proteasome in which the proteolytically active subunits PSMB1, PSMB2, and PSMB5 are replaced by alternative subunits PSMB9, PSMB10, and PSMB8, respectively. The immunoproteasome has broadly similar activity to the 20S proteasome but generates different peptides (16, 51). The immunoproteasome has been reported to play an important role in the generation of peptides for MHC class I antigen presentation, including reports that mice with a knockout of the immunoproteasome subunit PSMB8, or, in another study, a knockout of all 3 subunits, have severely compromised MHC class I antigen presentation and immunodeficiency (31, 32). The immunoproteasome also plays an important role in the degradation of...
oxidized proteins. All 3 immunoproteasome-specific subunits are upregulated under acute exposure to oxidative stress in cell culture (16, 29), and knockout of PSMB8 produces increased protein oxidation and decreased oxidative stress resistance in laboratory mice (29, 30). Our results show that immunoproteasome levels, as measured by PSMB8, are significantly higher in fibroblasts from mice (29, 30). Our results show that immunoproteasome levels, as measured by PSMB8, are significantly higher in fibroblasts from mice. (29, 30).

It is unclear what selective pressures have driven enhanced immunoproteasome levels in primates for which a long lifespan is selectively advantageous. It is possible that an enhancement in immunoproteasome function would increase cellular proteostatic capacity and turnover of oxidized or otherwise damaged proteins. Alternatively, enhancement in immunoproteasome may lead to an increase in MHC class I cell surface antigen presentation and in this way augment immune defenses to viral infection and cancer.

We also noted upregulation of other parts of the MHC class I antigen presentation system in cells from longer-lived primates, including TAP1 and TAP2 (33) as well as β-2 microglobulin (34). Interpretation of these findings is not straightforward. The genes encoding TAP1 and TAP2 are adjacent to immunoproteasome subunits PSMB8 and PSMB9 in the genome, and it is possible that these genes may be subjected to similar transcriptional controls. Although β-2 microglobulin is an important component of the MHC class I complex, it is also present in a large number of non-classical cell surface antigen presentation complexes (35). Thus our findings suggest a possible increase in MHC class I antigen presentation in immune responses of longer-lived primates, an idea that requires more detailed evaluation.

We also find differences in IFN-γ responsiveness between cells from long- and short-lived primate species, potentially reflecting higher levels of the IFNγR2 subunit of the IFN-γ receptor. IFNγR2 is a non-ligand binding protein in the IFN-γ receptor complex, but there is some evidence that it plays an important role in determining IFN-γ responsiveness. Immune cells with high expression of IFNγR2 are much more responsive to IFN-γ than are immune cells with low IFNγR2 expression (52), and mutation of IFNγR2 can enhance susceptibility to mycobacterial infection (53).

In this work and in our previous study of resistance to oxidative protein damage (1), the responses of cells from humans frequently do not fit well with regression lines computed using the non-human primate species. For most of the endpoints, fibroblasts from humans were similar to those of the other great apes, even though human lifespan is approximately twice that of non-human apes. This disparity is not likely to reflect simply greater access to healthcare in humans (compared, for example, to zoo animals), nor is it likely to be an artifact of differences in assessed sample size as, for example, most humans remain in good health at 45 to 50 years old, an age at which nearly all non-human primates have died. This disparity in lifespan is observable even in human populations that have only limited access to medication (54, 55). Further insights into the unexpectedly slow rate of aging in humans are likely to emerge from attention to cellular properties that discriminate human cells from the trends seen across a range of non-human primate species.

We also found an elevation in protein levels of the immunoproteasome subunit PSMB8 in liver tissue of laboratory mice in which mutations, or exposure to each of 3 drugs, led to extended lifespan. Two of the drugs also led to increased proteasomal function in mouse liver. The congruity between findings from comparative biology and results from mouse intervention protocols is consistent with the hypothesis that altered proteasome activity may regulate lifespan, both across species and within a single species. It is not yet clear how the Snell dwarf mutation, and the drugs tested, lead to extended lifespan, and it is possible that the effects on proteasome biology reflect different cellular or physiological mechanisms. Elevated immunoproteasome expression in Snell dwarf mice is unlikely to be caused by increases in IFN-γ responses because IFN-γ receptor levels are downregulated in Snell dwarf mice (56). Elevation of TNF-α levels, seen in Snell dwarf mice (57), is a potent inducer of immunoproteasome expression (58). Snell dwarf mice also showed increased levels of PSMB5 (see Supplemental Table 2 and Supplemental Figure 16), not seen in the drug-exposed mice, potentially a product of increased NRF2 signalling in Snell dwarf mice (59). We found higher PSMB8 immunoproteasome levels in livers from female mice (compared with males of the genetically heterogeneous UM-HET3 stock) and in male EST mice. In humans, IFN-γ has an estrogen-binding sequence in its promoter region and is more highly expressed in females (60). The growing availability of genetic, dietary, and pharmacological approaches to longevity extension in mice will help to clarify the pathways by which differences in proteasome structure and function may contribute to improved health in these mice and provide further illustrations of the ways in which discoveries in comparative biogerontology can guide explorations of aging in laboratory, and potentially clinical, settings.

**Methods**

**Cell culture.** Cells were cultured in DMEM (high-glucose variant; Gibco-Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum...
and antibiotics (100 U/ml penicillin, 100 μg/ml streptomycin and 0.25 μg/ml of amphotericin B; Gibco-Invitrogen). Cells were incubated at 3% O₂, hypoxic with respect to atmospheric O₂ concentration, to mimic their normal physiological environment; the incubators were also maintained at 5% CO₂, and 37°C. Medium was replaced every 3 to 4 days.

Most of the primates' primary fibroblast lines were purchased from the Integrated Primate Biomaterials and Information Resource collection held at the Coriell Institute for Medical Research. In some cases, primate cell lines were generated from skin biopsies obtained from the New England Regional Primate Research Center (Harvard University, Cambridge, Massachusetts, USA) and Southwest National Primate Research Center (Texas Biomedical Research Institute, San Antonio, Texas, USA). Cell lines were generated from these biopsies as described previously (1). In most instances the same cell lines were used for each set of experiments, but inconsistencies in cell growth sometimes led to substitution within a species or omission of a species from a specific data set. A list of which cell lines were used in each experiment as well as the Coriell line identification code (if applicable) is provided in Supplemental Table 1.

**Proteolytic activity assay.** Cells were seeded at 40,000 cells/cm². The medium was replaced 24 hours later with DMEM without serum but supplemented with 2% BSA and antibiotics. Cells were harvested through scraping 24 hours later, then lysed in proteolysis buffer (50 mM Tris-HCl pH 7.4, 5 mM MgCl₂, 1 mM DTT ± 0.25 mM ATP) through 3 freeze-thaw cycles. Protein content was measured using a Bradford assay, after which 2 μg of cell lysate was diluted to 100 μl and incubated with 50 μM Suc-LLVY-AMC (Sigma-Aldrich). Samples were allowed to equilibrate for 1 hour, after which fluorescence was recorded over the following 3 hours using Ex/Em: 370 nm/460 nm. We ran 4 replicates for each sample.

**In-gel activity assay.** Cells were lysed in proteolysis buffer (50 mM Tris-HCl pH 7.4, 5 mM MgCl₂, 1 mM DTT, and 5 mM ATP) through 3 freeze-thaw cycles. Protein content was normalized using a Bradford assay. Cell lysate was mixed with 10% glycerol plus 0.001% bromophenol blue. Samples were then run on a 10% native polyacrylamide gel at 4°C. Samples were run for 1 hour at 150 V and then for a further 3 hours at 250 V. Samples were run in native polyacrylamide gel running buffer (Invitrogen) supplemented with 0.1 mM ATP to maintain 26S proteasome structure (61). The gel was then incubated in proteolysis buffer supplemented with 0.01% SDS (to enhance 20S proteasome activity), 5 mM ATP (to enhance 26S proteasome activity), and 500 μM Suc-LLVY-AMC for 30 minutes at 37°C. The addition of low concentrations of SDS and ATP was done to enable visualization of both the 20S and 26S bands (62, 63). Fluorescence was measured under exposure to UV (312 nm) using the ImageQuant 4000 (GE Healthcare) fluorescence analyzer, which measured emissions between 585 and 625 nm (the tail end of the Suc-LLVY-AMC emission spectrum). Commercially purified 20S proteasome and 26S proteasome were run in each gel as a positive control (Enzo Life Sciences). Protein content was measured using a Coomassie stain. Aliquots of the above samples were run in parallel using an identical gel setup, but were then immunoblotted using either anti-PSMB8 or anti-PSMB8 (Abcam).

**RNA extraction and quantitative PCR.** Cells were seeded at 40,000 cells/cm²; medium was replaced after 24 hours with DMEM supplemented with 2% BSA and antibiotics. After 24 hours cells were harvested by incubation with Trizol (Gibco, Invitrogen). cDNA was prepared at 100 ng/μl using the iScript cDNA kit (Bio-Rad Laboratories). Sample cDNAs were analyzed in duplicate via quantitative RT-PCR. In the case of cross-species comparisons, samples were normalized with β-actin mRNA. However, in IFN-γ treatment experiments, samples were simply controlled by total mRNA loading because the differences measured were quite small and thus susceptible to distortions produced by pipetting accuracy between samples screened for the mRNA of interest and samples screened for β-actin. In some cases, where specified, cells were cultured in medium supplemented with 40 ng/ml recombinant rat IFN-γ for 24 hours prior to mRNA extraction.

**LD₅₀ assays.** LD₅₀ experiments were performed using WST-1 reagent as described previously (2, 3). Where specified in the figures, cells were cultured in media supplemented with 40 ng/ml of recombinant rat IFN-γ for 24 hours, prior to exposure to H₂O₂.

**ELISA assays.** Custom peptides were produced by Thermo Scientific. Peptides were diluted to a range of concentrations and fixed to a 96-well plate by incubation with 100 mM carbonate/bicarbonate solution overnight at 4°C. Samples were washed 4 times with PBS and then blocked with PBS supplemented with 5% BSA for 2 hours. Samples were then incubated with an antibody relevant to the protein in question in 5% BSA overnight at 4°C. Samples were then washed 4 times and incubated with a secondary horseradish peroxidase-conjugated antibody in 5% BSA overnight at 4°C. Samples were then washed 4 times and detected using a 3,3',5,5'-tetramethylbenzidine peroxidase substrate.

**Mice.** For drug treatment protocols, we used genetically heterogeneous mice (UM-HET3), bred as the progeny of C66F1 mothers and C3D2F1 fathers, following the husbandry protocols developed by the Interventions Testing Program of the National Institute of Aging (44). Mice were given rapamycin (14 ppm), acarbose (1,000 ppm), or EST (4.8 ppm) starting at 4 months of age and were euthanized at 12 months of age, or mice were given NDGA (2500 ppm for males and 5000 ppm for females, to produce equivalent NDGA blood levels) starting at 13 months of age, with euthanasia and tissue collection at 22 months (NDGA).

For Snell dwarf mice, DW/+/+ males and C3H/HeJ pw/− males heterozygote breeders purchased from Jackson Laboratory were crossed to produce (DW × C3H) F1 male mice used in these studies. The (DW × C3H) F1 mice included 3 genotypic groups: dw/dw, dw+/+, and +/+ . Mice of the dw/dw genotype were identified by small body size (dwarfs), and the other 2 genotypes, which are not phenotypically distinguishable, were considered as non-mutant controls (+/−). Snell dwarf mice and non-mutant controls were euthanized at 6 months (± 2 weeks).

For immunoblotting, tissues were chilled in liquid nitrogen and then homogenized using a pestle and mortar which had also been chilled with liquid nitrogen. The homogenate was incubated in RIPA buffer at 4°C for 15 minutes and was subjected to vortexing every 5 minutes. The homogenate was then centrifuged at 15,000 g for 5 minutes and the supernatant removed. Lysate protein content was determined using a BCA assay. Samples were mixed with Laemmli sample buffer supplemented with 5% β-mercaptoethanol and boiled at 95°C for 5 minutes prior to immunoblotting. For proteasomal activity assay, samples were treated as described above for cell culture.

**Statistics.** Values for MLS and adult body mass are given as reported on the AnAge online database (64) [http://genomics.senescence.info/species/]. Except where otherwise specified, P values and R² values for scatter plots were based on simple linear regressions. Comparisons of mice that differed in sex and drug exposure (or genotype) were evalu-
ated using a 2-factor ANOVA, yielding $P$ values for main effect of each term and for the (sex $\times$ treatment) interaction; significant ANOVA outcomes were followed by the post hoc least significant difference test. Protein and mRNA sequence data were provided by the NCBI. Multi-sequence alignments were performed using MAFFT software, version 7 (http://mafft.cbrc.jp/alignment/software/). In this study a $P$ value less than 0.05 was considered statistically significant.

**Study approval.** All mouse studies performed were approved by the University Committee on Use and Care of Animals at the University of Michigan (Ann Arbor, Michigan, USA) on December 7, 2012.

**Acknowledgments**

We wish to thank Bill Kohler and Melissa Han for generation, acquisition, and maintenance of the cell lines, Sabrina Van Roekel and Amanda Keedle for mouse husbandry and tissue preparation, Michael Garratt and Brian Bower for preparation of mouse tissues as well as advice on statistical analyses, and the New England Regional Primate Research Center and Southwest National Primate Research Center for obtaining skin biopsies from which cell lines were derived. This research was supported by the National Institute of Aging, a division of the NIH (grants P30-AG024824, U19-AG023122, R01-AG019899, and T32-AG000114), as well as by the Glenn Foundation for Medical Research.

Address correspondence to: Richard A. Miller, Department of Pathology and Geriatrics Center, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, Michigan 48109, USA. Phone: 734.936.2122; E-mail: millerr@umich.edu.